Skip to main content
Jon Cuthbert Profile pIcture
Jon Cuthbert

Jon Cuthbert

GrafaFounder & COO

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.

Articles by Jon Cuthbert

Grafa
Health

Mesoblast reshuffles board for commercial pivot as Ryoncil sales surge

Mesoblast (NASDAQ:MESO) has implemented a sweeping reorganization of its Board of Directors, effective January 1, 2026, signaling a definitive shift from a research-heavy biotech to a revenue-driven commercial entity.

The leadership transition follows the company's most transformational period, highlighted by the December 2024 FDA approval and subsequent 2025 launch of Ryoncil (remestemcel-L).

Read more